BNT162b2 2024-2025 Vaccine Effectiveness against COVID-19 in Children aged 6 months-17 years.

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Journal of the Pediatric Infectious Diseases Society Pub Date : 2026-04-03 DOI:10.1093/jpids/piag029

Sara Y Tartof, Tara Ahi, Timothy B Frankland, Jeff M Slezak, Joann M Zamparo, Bradley K Ackerson, Laura Puzniak

引用次数: 0

Abstract

In a test-negative case-control design among children aged 6 months-4 years (n=11,878) and 5-17 years (n=16,687) in Kaiser Permanente Southern California, BNT162b2 2024-2025 effectiveness against hospitalization/emergency department/urgent care/outpatient was 36% (95% CI: -5-61%) and 42% (-2-67%), respectively suggesting pediatric COVID-19 vaccination remains beneficial.

查看原文本刊更多论文

BNT162b2 2024-2025 6个月17岁儿童抗COVID-19疫苗有效性。

在南加州凯撒医疗机构的6个月至4岁（n=11,878）和5-17岁（n=16,687）儿童的测试阴性病例对照设计中，BNT162b2 2024-2025对住院/急诊科/急诊/门诊的有效性分别为36% （95% CI: -5-61%）和42%(-2-67%)，表明儿童COVID-19疫苗接种仍然有益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the Pediatric Infectious Diseases Society Medicine-Pediatrics, Perinatology and Child Health

CiteScore

6.70

自引率

0.00%

发文量

179

期刊介绍： The Journal of the Pediatric Infectious Diseases Society (JPIDS), the official journal of the Pediatric Infectious Diseases Society, is dedicated to perinatal, childhood, and adolescent infectious diseases. The journal is a high-quality source of original research articles, clinical trial reports, guidelines, and topical reviews, with particular attention to the interests and needs of the global pediatric infectious diseases communities.